Trials / Completed
CompletedNCT00262041
Study of the Safety and Immune Response of a Meningococcal Conjugate Vaccine Administered to Healthy Adolescents
A Phase 2, Randomized, Single-blind, Controlled, Multicenter Study to Compare the Safety and Immune Response of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With the Safety and Immune Response of One Dose of Licensed Meningococcal ACWY Polysaccharide Vaccine Administered to Healthy Adolescents 11 to 17 Years of Age
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 524 (actual)
- Sponsor
- Novartis Vaccines · Industry
- Sex
- All
- Age
- 11 Years – 17 Years
- Healthy volunteers
- —
Summary
The purpose of this study is to evaluate the safety and immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in comparison to licensed meningococcal polysaccharide vaccine administered to healthy adolescents ages 11 to 17 years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MenACWY-CRM conjugate vaccine, adjuvanted | |
| BIOLOGICAL | MenACWY-CRM conjugate vaccine, unadjuvanted | |
| BIOLOGICAL | MenACWY polysaccharide vaccine |
Timeline
- Start date
- 2004-10-01
- Primary completion
- 2006-03-01
- Completion
- 2006-03-01
- First posted
- 2005-12-06
- Last updated
- 2018-06-28
- Results posted
- 2013-11-20
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00262041. Inclusion in this directory is not an endorsement.